AbbVie Earnings: Skyrizi and Rinvoq Now Drive the Post-Humira Mix
AbbVie earnings for Q2 2026 make the company’s post-Humira transition much easier to quantify. Revenue reached $16.990 billion, up 10.2% year over year on a reported basis, but the more revealing change is inside the product mix. Skyrizi generated $5.505 billion of quarterly revenue and Rinvoq produced $2.525 billion. Together, those two products accounted for … Read more